Skip to main content
Research Use Only 57-Product Catalog Flexible Order Quantities Batch-Document Support U.S. Fulfilment for Selected Stock Tracked Shipping Options Custom Synthesis & OEM Research Use Only 57-Product Catalog Flexible Order Quantities Batch-Document Support U.S. Fulfilment for Selected Stock Tracked Shipping Options Custom Synthesis & OEM
Home/Products/Tesamorelin

Material & batch records

Tesamorelin

Compare the material specification with the scope of the available records.

Tesamorelin — existing catalog illustration
Existing catalog illustration. A pictured label is not a batch result and may differ from the selected specification.

Modified GHRH analogue / Material & batch records

Modified GHRH analogue
Specification & documents

Tesamorelin is a modified GHRH analogue. Its identity is distinct from sermorelin and from intact growth hormone.

MATERIALTesamorelin
SPECIFICATION2 catalog options
DOCUMENT SCOPEConfirm the offered lot
USELaboratory research only
Catalog specification — select for your inquiry

Selected: 5 mg × 10 vials

Nominal catalog options, not a live availability guarantee. Final supply is confirmed in the written quotation.

Evidence for the offered material

Batch records

Published attachments are available below. Match each record to the material and lot being quoted.

Existing published attachment · 1

Review the original record

Check the sample identity, batch, report identifier and nominal quantity in the attachment. Publication on this page does not independently authenticate the report or establish its applicability to current stock.

Open published attachment ↗
Identity

Confirm the modification, complete sequence specification and counter-ion. For a combination request, state each component and amount separately.

Analytical scope

Ask which tests and underlying files are available, what each result measures and which batch it covers. Do not infer a test result from an image or badge.

Order match

Match product name, selected specification, lot reference and packaging to the quotation. Ask about any difference before confirming supply.

Material profile

Material identity

Tesamorelin is a modified GHRH analogue. Its identity is distinct from sermorelin and from intact growth hormone.

For Tesamorelin, a document is useful only when its sample description matches the requested material. This page keeps reference identity, catalog quantities and batch-document scope separate.

The key distinction
Confirm the modification, complete sequence specification and counter-ion. For a combination request, state each component and amount separately.

Catalog & quotation

Catalog specification

Catalog materialTesamorelin
Material classModified GHRH analogue
Listed options5 mg × 10 vials
10 mg × 10 vials
Catalog reference CAS218949-48-5Reference field only; confirm it matches the supplied form.
Catalog reference formulaC221H366N72O67SReference field only; confirm it matches the supplied form.
Catalog reference molecular weight5136 g/molReference field only; confirm it matches the supplied form.
Identity / supplied formConfirm the modification, complete sequence specification and counter-ion. For a combination request, state each component and amount separately.
Identity, purity and contentRequest the method, acceptance specification and lot-specific results. Chromatographic purity and net material content are separate measurements.
Storage / stabilityFollow the written instructions for the actual material and batch. No universal 24-month shelf life or solution stability is assumed.
Catalog options are inquiry specifications, not a live stock feed. The final quotation must confirm the material, amount, packaging and document scope.

Scientific context

Research background

Research using tesamorelin concerns that modified sequence and the study formulation. It does not authenticate this catalog supply or establish a use protocol.

01

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

The Journal of clinical endocrinology and metabolism · 2010 · PMID 20554713

Read the named material, experimental model, controls and limitations in the original paper. This source is scientific background, not a certificate for the offered lot.

Read the primary publication ↗
02

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

JAMA · 2014 · PMID 25038357

Read the named material, experimental model, controls and limitations in the original paper. This source is scientific background, not a certificate for the offered lot.

Read the primary publication ↗

For laboratory research use only. Not for human or veterinary use, diagnosis or therapeutic application. No administration or dosing protocol is provided.

Before you inquire

Document questions

What differentiates this request from a sermorelin request?

Confirm the modification, complete sequence specification and counter-ion. For a combination request, state each component and amount separately.

What should my Tesamorelin inquiry include?

Include the exact material name, the catalog option or required specification, quantity, destination and any documents needed before quotation. Keep nominal amount per container separate from the number of containers.

Does the catalog image confirm the selected specification?

No. It is a catalog illustration. The image may show one variant while the selector lists other options. Use the written quotation and matching batch documents to confirm supply.

Does a paper or an existing report validate every future batch?

No. A paper describes its studied material and model. An analytical report describes a named sample. Confirm the connection between any report and the lot offered for your order.

Catalog content reviewed 26 September 2026. Listed options are from this site's product records. Scientific sources, where shown, describe research context, not batch certification.

Connect the material to the document.

Include the material, amount and evidence your laboratory needs to review.

Prepare an inquiry